Business Wire

THALES

Share
China, South Korea and Turkey Select Thales’ Technologies for Their Metros

Thales will provide its SelTrac™ Communications Based Train Control (CBTC) signalling solution in South Korea, Turkey and China, after signing three urban rail signalling contracts. Despite the current Covid-19 pandemic, governments around the globe are committed to progressing forward with crucial public transportation developments and Thales’s technology will be an important part of these projects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005010/en/

Incheon Metro, Line 2 Capacity Increase

Incheon Subway Line 2 is part of the overall Seoul Metropolitan Subway network, which is currently undergoing modernisation to improve the performance and reliability of the network.

Thales has signed a contract with DaeaTi, a leading Korean railway signalling technology player, to provide new signalling equipment for the Incheon Line 2 depot capacity increase, which will address the need to park the six new driverless trains safely. The trains will be delivered in 2021 with Thales’ Vehicle On Board Controller (VOBC) which were separately contracted with train contractor Woojin Ind in 2019. Since the start of revenue service of Incheon’s L2 metro in July 2016, passenger flow has doubled from 90,000 to 180,000 a day, prompting the need for six additional trains to cope with the increase.

Thales has been working with Incheon City and Incheon Transit Corporation since 2009 on the Incheon Line 2, focusing on better serving the public transit users of Incheon as their common goal.

Istanbul Metro, Line M10

The M10 Line will be the first metro line to the Sabiha Gokcen International Airport, the second busiest airport in Turkey, on the Asian side of Istanbul and will comprise 7.5km of track and four stations. Gülermak-YSE Joint Venture is the main project contractor, and Thales has been contracted by Çelikler Taahhut, a major construction company, to install their SelTrac™ CBTC system on the new M10 Line in Istanbul Turkey, connecting the Kaynarca district and the Sabiha Gokcen Airport. The M4 line is already equipped with Thales’s SelTrac™ solution and the new contract will extend the existing technology onto the new line.

Upon completion, the new line will allow connectivity between the Airport and major cities, taking 13 minutes from the airport to Kaynarca, 46 minutes to Kadikoy and an hour to Yenikapı, on the European side. This project is part of the Government of Turkey’s key priorities to improve transportation in major cities , with a strong focus on connectivity between transportation hubs.

Nanchang Metro, Line 4

Thales SEC Transportation System Company Limited (TST), Thales’ Joint Venture with Shanghai Electric, will provide the signalling for the first phase of the new metro Line 4 in Nangchang, the capital and largest city of the Jiangxi Province in eastern China. The first phase of the Nanchang Metro Line 4 will expand from Baimashan Station to Yuweizhou Station, passing through the main area of Nanchang to connect five districts. The first phase of the Nanchang Metro Line 4 has a total operational length of 39.6km, with 34.1km underground, 5.5km elevated and 29 stations, making it the longest metro line in Nanchang, with the largest number of stations. .

TST is familiar with the network as they have previously delivered signalling systems to the Line 1 and Line 2 of the Nangchang Metro. This project will allow the Nanchang Metro to continue to support the rapidly growing population of Nanchang.

In parallel in China, on April 23rd, Hangzhou Metro Line 16, connecting Hangzhou downtown with Lin’an District, entered into revenue service smoothly. This very fast metro line relies on Thales SEC Transport signalling system technologies for maximum safety and efficiency, ensuring everyday pleasant and reliable journeys for local passengers and showing Thales commitment to China ground transportation.

“During the Covid-19 period, we are continuing to work together with our global partners in major cities such as Incheon, Istanbul, and Nanchang. Thales is committed to providing state-of-the-art SelTrac™ CBTC signalling technology. No matter the network or city, we continue to tailor our solution to meet the needs of the customer and provide reliable transportation solutions for their passengers.” – Dominique Gaiardo, Vice President and Managing Director for Thales’ urban rail signalling business.

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT
Thales Group
Transportation

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye